Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Side effects are rare. Reported adverse events include seizures, changes in color vision, blood clots, and allergic reactions such as anaphylaxis. Whether the risk of venous thromboembolism (blood clots) is increased is a matter of debate. The risk is mentioned in the product literature, and they were reported in post marketing experience. Despite this, and the inhibitory effect of tranexamic acid on blood clot breakdown, large studies of the use of tranexamic acid have not shown an increase in the risk of venous or arterial thrombosis, even in people who had previously experienced thrombosis under other circumstances. For pregnancy, no harm has been found in animal studies. Small amounts appear in breast milk if taken during lactation. Tranexamic acid was first synthesized in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines.
China is the main supplier of wolfberry products globally, with 2023 production derived from a cultivation area of 325,000 mu – about 21,667 ha (53,540 acres) – creating a national wolfberry economy of 29 billion yuan (approximately US $4.2 billion). Some 61% of commercially produced wolfberries in China comes from L. barbarum plantations in the Ningxia region, mainly in Zhongning County. Goji cultivation also occurs in Gansu, Qinghai Province, and the Haixi Mongol and Tibetan Autonomous Prefecture. The main berry products for export are manufactured beverages, juice concentrate, dried berries, snacks, and freeze-dried juice powder and berries. Ningxia goji has been cultivated along the fertile floodplains of the Yellow River over centuries. The region has developed an industrial association of growers, processors, marketers, and scholars of wolfberry cultivation to promote the berry's commercial and export potential. Ningxia goji berries, the variety used by practitioners of traditional Chinese medicine, are celebrated annually with a festival.
Investigators have hypothesized that the PHLPP isoforms may play roles in cancer, for several reasons. First, the genetic loci coding for PHLPP1 and 2 are commonly lost in cancer. The region including PHLPP1, 18q21.33, commonly undergoes loss of heterozygosity (LOH) in colon cancers, while 16q22.3, which includes the PHLPP2 gene, undergoes LOH in breast and ovarian cancers, Wilms tumors, prostate cancer and hepatocellular carcinoma. Second, experimental overexpression of PHLPP in cancer cell lines tends to decrease apoptosis and increase proliferation, and stable colon and glioblastoma cell lines overexpressing PHLPP1 show decreased tumor formation in xenograft models. Recent studies have also shown that Bcr-Abl, the fusion protein responsible for chronic myelogenous leukemia (CML), downregulates PHLPP1 and PHLPP2 levels, and that decreasing PHLPP levels interferes with the efficacy of Bcr-Abl inhibitors, including Gleevec, in CML cell lines. Finally, both Akt and PKC are known to be tumor promoters, suggesting that their negative regulator PHLPP may act as a tumor suppressor.
Mammals begin carbohydrate synthesis with monosaccharides, which come from either gluconeogenesis or the breakdown of complex carbohydrates. Gluconeogenesis begins with pyruvate, which comes from alanine and α-ketoglutarate amino acids. This process only begins when glycogen storages are near depletion due to the higher ATP cost of metabolising proteins into amino acids. Conversely, plants undergo the Calvin cycle to photosynthesize glucose-3-phosphate from CO2 and H2O in the presence of light; the phosphate is quickly hydrolyzed into glucose.
The United States detonated an experimental device in the 1955 Operation Teapot "MET" test which used a plutonium/233U composite pit; its design was based on the plutonium/235U pit from the TX-7E, a prototype Mark 7 nuclear bomb design used in the 1951 Operation Buster-Jangle "Easy" test. Although not an outright fizzle, MET's actual yield of 22 kilotons was sufficiently below the predicted 33 kt that the information gathered was of limited value. The United States conducted several additional weapons tests with 233U for unknown purposes. The Soviet Union detonated its first hydrogen bomb the same year, the RDS-37, which contained a fissile core of 235U and 233U. In 1998, as part of its Pokhran-II tests, India detonated an experimental 233U device of low-yield (0.2 kt) called Shakti V. The B Reactor and others at the Hanford Site optimized for the production of weapons-grade material have been used to manufacture 233U. The United States Atomic Energy Commission used the weapons production reactors at Hanford to breed significant quantities of 233U from thorium for use in both nuclear weapons and for civilian research. Overall the United States is thought to have produced two tons of 233U, of various levels of purity, some with 232U impurity content as low as 6 ppm. The hazards are significant even at 5 parts per million. Implosion nuclear weapons require 232U levels below 50 ppm (above which the 233U is considered "low grade"; cf.
Sources: en.wikipedia.org
Insulin is usually given subcutaneously, either by injections or by an insulin pump. In acute care settings, insulin may also be given intravenously. Insulins are typically characterized by the rate at which they are metabolized by the body, yielding different peak times and durations of action. Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods. Examples of rapid-acting insulins (peak at ~1 hour) are:
=== Plant protection products === Plant protection products contain surfactants to improve wetting (spreading) on plants. The most common wetting agent is ethoxylated tallow amine. Trisiloxanes or polyoxyethylated fatty alcohols are also used. Agrochemical formulations that use surfactants include herbicides (some), insecticides, biocides (sanitizers).
Bowery Poetry is a performance space at Bowery and Bleecker Street. It was founded in 2001 as Bowery Poetry Club (BPC), and provided a home base for established and upcoming artists. It was founded by Bob Holman, owner of the building and former Nuyorican Poets Café Poetry Slam MC (1988–1996). The BPC featured regular shows by Amiri Baraka, Anne Waldman, Taylor Mead, Taylor Mali, along with open mic, gay poets, a weekly poetry slam, and an Emily Dickinson Marathon, amongst other events. The club closed in 2012 and reopened in 2013 as a shared performance space under the name "Bowery Poetry". Bowery Arts + Science presents poetry, and Duane Park presents alternative burlesque in this space.
Neurotransmitter binds to the receptor The receptor undergoes a conformational change to allow G-protein complex binding GDP is exchanged with GTP upon G protein complex binding to the receptor The α-subunit of the G protein complex is bound to GTP and separates to bind with a target protein such as adenylate cyclase The binding to the target protein either increases or decreases the rate of second messenger (such as cyclic AMP) production GTPase hydrolyzes the α-subunit so that is bound to GDP and the α-subunit returns to the G protein complex inactive
=== Learning and memory === A study at the European Neuroscience Institute-Goettingen (Germany) found that fear extinction-induced IGF2/IGFBP7 signalling promotes the survival of 17- to 19-day-old newborn hippocampal neurons. This suggests that therapeutic strategies that enhance IGF2 signalling and adult neurogenesis might be suitable to treat diseases linked to excessive fear memory such as PTSD. The same group has found that IGFBP7 levels are increased in Alzheimer's disease and regulated via DNA methylation. Elevation of IGFBP7 in wild type mice causes memory impairment. Blocking IGFBP7 function in mice that develop Alzheimer's disease-like memory impairment restores memory function. These data suggest that IGFBP7 is a critical regulator of memory consolidation and might be used as biomarker for Alzheimer's disease. Targeting IGFBP7 could be a novel therapeutic avenue for the treatment of Alzheimer's disease patients.
Sources: en.wikipedia.org
===== Caffeine ===== A 2025 study suggests that caffeine may help with hair growth by stimulating hair follicles and counteracting the effects of DHT, a hormone linked to hair loss. Caffeine is believed to increase blood circulation in the scalp and extend the hair's growth phase, which could potentially help slow down the hair thinning process. While caffeine-based hair products are popular, more research is needed to fully confirm their effectiveness.
Neurotmesis is total severance/disruption of the nerve fiber. Axon, endo-, peri-, and epineurium transected. Neurotmesis will result in complete sensory and motor deficits in the affected area. Other characteristics:
=== Proteins and nucleic acids === Daly developed methods for separating out the nuclei of tissues and measuring the base composition of purines and pyrimidines in desoxypentose nucleic acids. She concluded, among other things, that "no bases other than adenine, guanine, thymine, and cytosine were present in appreciable amounts." She investigated protein synthesis, including the role of cytoplasmic ribonucleoprotein in protein synthesis. Using radiolabeled amino acid glycine, she was able to measure how protein metabolism changed under feeding and fasting conditions in mice. This allowed her to monitor the activity of the cytoplasm as the radiolabeled glycine was taken up into the cell nucleus. In 1953, Watson and Crick described the structure of DNA. Accepting the Nobel Prize for this work in 1962, Watson cited one of Daly's papers on "The role of ribonucleoprotein in protein synthesis" as contributing to his work. After 1953, the cell nucleus research field was flooded with funding opportunities.
== Research == PPAR-gamma agonists have been used in the treatment of hyperlipidaemia and hyperglycemia. Many insulin sensitizing drugs (namely, the thiazolidinediones) used in the treatment of diabetes activate PPARG as a means to lower serum glucose without increasing pancreatic insulin secretion. Activation of PPARG is more effective for skeletal muscle insulin resistance than for insulin resistance of the liver.
==== Mechanical interlocking ==== The bioadhesives have the ability to diffuse and penetrate the pores and irregularities in the surface it is adhered to which forms a close interlock. This increases the contact area of the too surfaces and results in an increase in adhesive force. In bioinspired adhesive systems the application of Chitosan, was used as a bridging polymer in a 3D hydrogel network to perform topological wet adhesion. By creating strong physical bonds between synthetic materials, by creating non covalent bonds between H bonds. It was shown that Chitosan causes rapid cohesion 1000 J·m⁻² by 3 and 2000 J·m⁻² by 10 min. Chitosan diffuses and soaks which causes chitosan to move into the polyacrylamide mesh and weave themselves through. Chitosan penetrates deep as ~ 25 μm in tendon and skin after 10 min and 1h of compression respectively.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.